Search

Your search keyword '"Geng, Zhaoxu"' showing total 12 results
Start Over Author "Geng, Zhaoxu"
12 results on '"Geng, Zhaoxu"'

6. Data-driven subgroups of newly diagnosed type 2 diabetes and the relationship with cardiovascular diseases of genetic and clinical levels in Chinese adults

Author

Wang, Weihao, primary, Jia, Tong, additional, Liu, Yiying, additional, Deng, Hongrong, additional, Chen, Zihao, additional, Wang, Jing, additional, Geng, Zhaoxu, additional, Wei, Ran, additional, Qiao, Jingtao, additional, Ma, Yanhua, additional, Jiang, Xun, additional, Xu, Wen, additional, Shao, Jian, additional, Zhou, Kaixin, additional, Li, Ying, additional, Pan, Qi, additional, Yang, Wenying, additional, Weng, Jianping, additional, and Guo, Lixin, additional

Published
2023
Full Text
View/download PDF

11. KCNQ1Variant rs163184 is a Potential Biomarker of Glycemic Response to Exenatide

Author

Geng, Zhaoxu, Li, Qian, Huang, Rong, Wang, Jing, Weng, Jianping, Zhou, Kaixin, Liang, Hua, and Wang, You

Abstract

Aim:To examine the association between variant rs163184 in the type 2 diabetes mellitus (T2DM) susceptibility gene KCNQ1and exenatide glycemic response in the Chinese population. Patients & methods:We included 100 T2DM patients from the CONFIDENCE study and investigated the association between rs163184 and glycemic response to exenatide, by using a multivariate linear model with adjustment for baseline glucose status and other covariates. Results:The G allele of rs163184 was associated with a 0.34% (p = 0.016) lower glycosylated hemoglobin reduction after 48 weeks of exenatide treatment. Similar significant associations were observed when glycemic response to exenatide was evaluated with fasting blood glucose or postprandial blood glucose reduction. Conclusion:We found that rs163184 in the gene KCNQ1was associated with reduced glycemic response to exenatide in T2DM patients. The effect size observed in this study was large enough to be considered clinically relevant in stratified medicine.

Published
2022
Full Text
View/download PDF

12. PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.

Author

Geng Z, Zheng Y, Li Q, Pan D, Lu X, Chen F, Zhang Y, Li K, Zhou K, Shi L, and Wang Y

Abstract

Background: Our objective was to explore the pharmacogenetic impact of three known functional variants in drug target genes and determine whether they can explain the inter-individual variation in therapeutic response., Methods: In a post hoc analysis of data from randomized controlled clinical trials of chiglitazar, we genotyped 481 Chinese patients with T2DM and investigated the association of variants in PPAR genes with the therapeutic outcome separated by dose using linear regression., Results: rs1800234, a gain-of-function variant of PPARA, had a dose-dependent pharmacogenetic impact on the therapeutic response to chiglitazar. The C allele was significantly associated with reduced therapeutic response in the 48 mg group, while no significant association was observed in the 32 mg group. In addition, in patients without the C allele, patients treated with 48 mg chiglitazar had a better therapeutic response than those treated with 32 mg chiglitazar. To the contrary, in patients with the C allele, patients treated with 48 mg chiglitazar had a worse therapeutic response than those treated with 32 mg of chiglitazar., Conclusion: The PPARA variant rs1800234 had a dose-dependent pharmacogenetic impact on the therapeutic response to chiglitazar. It could help explain the absence of a dose effect of chiglitazar and serve as a potential biomarker for the chosen dose of chiglitazar in the future. In addition, our study provided important reference for the design and clinical application of multi-target drugs.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results